Phenotype and function of circulating memory T cells in human vitiligo*

Martins, Christina; Darrigade, A.-S.; Jacquemin, Clément; Barnetche, Thomas; Taı̈eb, Alain; Ezzedine, Khaled; Boniface, Katia; Sénéschal, Julien

doi:10.1111/bjd.18902

Cited by 18 publications

(21 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous research evidence chronicled that multiple components in PBMCs participate in the pathogenesis of vitiligo 14 . Analysis of divergently expressed miRNAs in PBMCs of patients with NSV exhibited that miR‐224‐3p and miR‐4712‐3p were upmodulated and miR‐3940‐5p expression was down‐regulated relative to the healthy controls.…”

Section: Discussionmentioning

confidence: 99%

Differentially expressed microRNAs in peripheral blood mononuclear cells of non‐segmental vitiligo and their clinical significance

Zhang

Yang

Liu

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Vitiligo is a frequent acquired depigmentation skin disease due to a loss of melanocytes. This study sought to characterize the expression pattern of microRNA (miRNA) in the peripheral blood mononuclear cells (PBMCs) of non‐segmental vitiligo (NSV) patients. We also screened for molecular markers that can be used to evaluate the clinical stages of NSV. Methods The miRNA expression profile in the PBMCs of four patients with progressive NSV and four healthy controls was determined using high‐throughput RNA sequencing. The divergently expressed miRNA was verified via qRT‐PCR in 26 progression, 26 stable NSV, and 26 healthy controls. Results Our findings posited that 323 miRNAs were differentially expressed in the PBMCs of NSV patients. The top 10 up‐regulated miRNAs in patients were hsa‐miR‐335‐5p, hsa‐miR‐20a‐5p, hsa‐miR‐514a‐3p, hsa‐miR‐144‐5p, hsa‐miR‐450b‐5p, hsa‐miR‐369‐3p, hsa‐miR‐101‐3p, hsa‐miR‐142‐5p, hsa‐miR‐19b‐3p, and hsa‐miR‐340‐5p. The top 10 down‐regulated miRNAs in patients were hsa‐miR‐4443, hsa‐miR‐1248, hsa‐miR‐6859‐3p, hsa‐miR‐668‐3p, hsa‐miR‐7704, hsa‐miR‐323a‐5p, hsa‐miR‐1237‐3p, hsa‐miR‐3127‐3p, hsa‐miR‐6735‐3p, and hsa‐miR‐127‐3p. The expressions of hsa‐miR‐20a‐5p in PBMCs of progressive and stable NSV were remarkably elevated relative to the healthy controls. In the characteristics curve analysis of hsa‐miR‐20a‐5p for differentiating progressive and stable NSV from normal subjects in PBMCs, the area under curve (AUC) was 0.92 and 0.81. Compared with patients in stable NSV, the hsa‐miR‐20a‐5p was markedly increased in PBMCs of progressive NSV patients, and the AUC was 0.81. Conclusion Our results showed that divergently expressed miRNAs contribute to the pathogenesis of NSV and that hsa‐miR‐20a‐5p can be applied as a biosignature for stage assessment in PBMCs of patients with NSV.

show abstract

Section: Discussionmentioning

confidence: 99%

Differentially expressed microRNAs in peripheral blood mononuclear cells of non‐segmental vitiligo and their clinical significance

Zhang

Yang

Liu

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…In addition to indications that T helper type 1/cytotoxic T lymphocyte (Th1/Tc1) subsets are involved in vitiligo, data suggest that more heterogeneous lymphocyte subsets are also implicated in the pathogenesis of this disease [46,47]. Future studies are required to dissect the role of the different immune T-cell subsets in vitiligo before investigating therapeutic options that target them.…”

Section: T Helper Type 1-skewed Immune Profile In Vitiligomentioning

confidence: 99%

Vitiligo, From Physiopathology to Emerging Treatments: A Review

Migayron

Boniface

Sénéschal

2020

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Vitiligo is a chronic inflammatory skin disease leading to the loss of epidermal melanocytes. To date, treatment options for vitiligo patients are limited, lack sustained efficacy, and are mainly based on off-label use of immunosuppressive agents, such as systemic or topical steroids or topical calcineurin inhibitors, in association with the use of ultraviolet light. However, recent insights into the understanding of the immune pathogenesis of the disease have led to the identification of several therapeutic targets and the development of targeted therapies that are now being tested in clinical trials. In this review, based on the physiopathology of the disease, we summarize emerging targets that could be developed for the treatment of vitiligo and discuss recent and ongoing developments of drugs for the management of the disease.

show abstract

“…Many studies on patients with vitiligo focus exclusively on patients with active disease. However, Martins et al 3 show that the same immune response is found in the blood of patients with active and stable disease. Previous studies have shown the presence of T RM cells in vitiligo skin, [4][5][6] which are likely involved during flares, as previously shown in psoriasis.…”

mentioning

confidence: 97%

“…In this issue of the BJD, Martins et al reaffirm the role of Th1 and Tc1 cell subsets in vitiligo disease and its production of both IFN-c and TNF-a. 3 Furthermore, their results show that the frequency of CD4 + and CD8 + circulating Th17/Tc17, Th1/Th17 and Tc1/Tc17 effector memory T-cell subsets is significantly lower in patients with vitiligo (both with stable and active disease) and psoriasis, in comparison with healthy donors. These findings suggest a possible migration of distinct T-cell subsets from the blood into the skin.…”

mentioning

confidence: 98%

“…4 A single-arm pilot study using secukinumab showed that directly targeting the IL-17 pathway is not a reliable strategy in vitiligo. 10 The work of Martins et al 3 raises important questions, such as whether pathogenic IFN-c-producing cells also secrete IL-17 in patients with vitiligo or whether the IL-17 production is a consequence of the activation of Th1/Th17 or Tc1/Tc17 cells.…”

mentioning

confidence: 99%

See 1 more Smart Citation